<html><body>  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human 
use   ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of  new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> q1a(r2)   current step 4 version dated 6 february 2003         this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich process.  at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa.      q1a(r2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history   first codification history date new codification november 2005 q1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 16 september 1992 q1 q1a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. q1 was renamed q1a. 27 october 1993 q1a q1a(r) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the first revision under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 7 october 1999 q1a(r1) q1a(r) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the first revision under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 8 november 2000 q1a(r1) current step 4 version q1a(r2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the second revision <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">directly</a></span> under step 4 without further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>, to include consequences of the 
adoption of q1f (stability data <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> for 
registration applications in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span> iii and 
iv), and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three 
ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 6 february 2003 q1a(r2)     cover note for revision of q1a(r) stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of  new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  the purpose of this note is to outline the changes made in q1a(r) that result from adoption of ich q1f ﬁstability data <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> for registration applications in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span> iii and ivﬂ. these changes are:  1. the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition has been changed from 30°c ± 2°c/60% rh ± 5% rh to 30°c ± 2°c/65% rh ± 5% rh in the following <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span>:  2.1.7.1  drug substance - <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions - general case  2.2.7.1  drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> - <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions - general case  2.2.7.3  drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>  3  glossary - ﬁintermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testingﬂ</a></span>  2. 30°c ± 2°c/65% rh ± 5% rh can be a suitable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition to 25°c ± 2°c/60% rh ± 5% in the following <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span>:  2.1.7.1  drug substance - <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions - general case  2.2.7.1  drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> - <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions - general case  3. 30°c ± 2°c/35% rh ± 5% rh has been added as a suitable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition to 25°c ± 2°c/40% rh ± 5% and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponding</a></span> 
example for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span>-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rates has been included in the following 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span>:  2.2.7.3  drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>  mid-stream switch of the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition from 30°c ± 2°c/60% rh ± 5% rh to 30°c ± 2°c/65% rh ± 5% rh can be appropriate provided that the respective <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and the date of the switch are clearly <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">documented</a></span></a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span> in the registration application.  it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> that registration applications <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contain</a></span> data from complete studies at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition 30°c ± 2°c/65% rh ± 5% rh, if applicable, by three years after the date of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">publication</a></span> of this revised <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in the respective ich tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">region</a></span></a></span>.     i stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of  new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> first <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption at step 4 of the ich process on 27 october 1993. revised under step 2 of the ich process on 7 october 1999 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption at step 4 of the ich process on 8 november 2000.  this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been revised a second time and has reached step 4 of the ich process at the ich steering committee meeting on 6 february 2003. it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich   table of contents 1. introduction.....................................................................................................1 1.1. objectives of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>........................................................................................1 1.2. scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>................................................................................................1 1.3. general principles......................................................................................................1 2. guidelines .......................................................................................................1 2.1. drug substance .......................................................................................................1 2.1.1. general .......................................................................................................1 2.1.2. stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>.................................................................................................1 2.1.3. selection of batches........................................................................................2 2.1.4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system.............................................................................2 2.1.5. specification....................................................................................................2 2.1.6. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency..........................................................................................3 2.1.7. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions.........................................................................................3 2.1.8. stability commitment....................................................................................5 2.1.9. evaluation .......................................................................................................5 2.1.10. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span>......................................................................................6 stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> t  2.2. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> .......................................................................................................6 2.2.1. general .......................................................................................................6 2.2.2. photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>.....................................................................................6 2.2.3. selection of batches........................................................................................6 2.2.4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system..............................................................................7 2.2.5. specification.....................................................................................................7 2.2.6. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency...........................................................................................7 2.2.7. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions..........................................................................................8 2.2.8. stability commitment...................................................................................12 2.2.9. evaluation .....................................................................................................12 2.2.10. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span>.....................................................................................13 3. glossary .....................................................................................................13 4. references .....................................................................................................17 ii  1 stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 1. introduction  1.1. objectives of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> the following <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is a revised version of the ich q1a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> and defines the stability data <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> for a new drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that is sufficient for a registration application within the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regions</a></span></a></span> of the ec, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span>, and the united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span>. it does not seek necessarily to cover the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for registration in or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/946">export</a></span> to other areas of the world. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> seeks to exemplify the core stability data <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> for new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, but leaves sufficient flexibility to encompass the variety of 
different practical situations that may be encountered due to specific scientific considerations and characteristics of the materials being evaluated. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> approaches can be used when there are scientifically justifiable reasons. 1.2. scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> addresses the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> to be submitted in registration applications for new molecular entities and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> does not currently seek to cover the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> to be submitted for abbreviated or abridged applications, variations, clinical trial applications, etc.  specific details of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sampling</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for particular dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> in their proposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closures are not covered in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> on new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> and on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> can be found in ich guidelines q1c and q5c, respectively. 1.3. general principles the purpose of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is to provide <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> on how the quality of a drug 
substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> varies with time under the influence of a variety of environmental factors such as temperature, humidity, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>, and to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> a re-
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period for the drug substance or a shelf life for the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions. the choice of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> conditions defined in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is based on an analysis of the 
effects of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> conditions in the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regions</a></span></a></span> of the ec, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and the united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span>. the mean kinetic temperature in any part of the world can be derived from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> data, and the world can be divided into four <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span>, i-iv. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> addresses <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span> i and ii. the principle has been <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> that stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> generated in any one of the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regions</a></span></a></span> of the ec, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and 
the united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> would be mutually acceptable to the other two <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regions</a></span></a></span>, provided the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> is consistent with this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> is in accord with <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> requirements. 2. guidelines 2.1. drug substance 2.1.1. general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> on the stability of the drug substance is an integral part of the systematic approach to stability evaluation.  2.1.2. stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 2 stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the drug substance can help identify the likely degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, which can in turn help <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the degradation pathways and the intrinsic stability of the molecule and validate the stability indicating power of the analytical 
procedures used. the nature of the stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the individual drug substance and the type of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> involved. stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is likely to be carried out on a single batch of the drug substance.  it should include the effect of temperatures (in 10°c increments (e.g., 50°c, 60°c, etc.) 
above that for accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>), humidity (e.g., 75% rh or greater) where appropriate, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2213">oxidation</a></span>, and photolysis on the drug substance.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should also evaluate the susceptibility of the drug substance to hydrolysis across a wide range of ph values when in solution or suspension.  photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be an 
integral part of stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> conditions for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> are described in ich q1b. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examining</a></span> degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> under stress conditions is useful in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> 
degradation pathways and developing and validating suitable analytical procedures.  however, it may not be necessary to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examine</a></span> specifically for certain degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> if it has been demonstrated that they are not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formed</a></span> under accelerated or 
long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions. results from these studies will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> an integral part of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> provided to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities. 2.1.3. selection of batches data from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies should be provided on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three primary batches of the drug substance. the batches should be manufactured to a minimum of 
pilot scale by the same synthetic route as, and using a method of manufacture and 
procedure that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulates</a></span> the final process to be used for, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches.  the overall quality of the batches of drug substance placed on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies should be representative of the quality of the material to be made on a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> 
scale. other supporting data can be provided. 2.1.4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system the stability studies should be conducted on the drug substance <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system that is the same as or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulates</a></span> the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and distribution. 2.1.5. specification specification, which is a list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, reference to analytical procedures, and proposed acceptance criteria, is addressed in ich q6a and q6b.  in addition, specification for degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in a drug substance is discussed in q3a. stability studies should include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of those attributes of the drug substance that are susceptible to change during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and are likely to influence quality, safety, and/or efficacy. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover, as appropriate, the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological attributes. validated stability-indicating analytical procedures should be applied. whether and to what extent replication should be performed will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the results from validation studies.  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 3 2.1.6. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency for long term studies, frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be sufficient to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the stability profile of the drug substance. for drug substances with a proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 12 months, the frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should normally be every 3 months over the first year, every 6 months over 
the second year, and annually thereafter through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of three time points, including the initial and final time points (e.g., 0, 3, and 6 months), from a 6-month study is 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>. where an expectation (based on development experience) exists that results from accelerated studies are likely to approach significant change criteria, 
increased <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted either by adding <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the final time point or by including a fourth time point in the study design. when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition is called for as a result of 
significant change at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of four time points, including the initial and final time points (e.g., 0, 6, 9, 12 months), from a 12-
month study is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>. 2.1.7. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions in general, a drug substance should be evaluated under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (with appropriate tolerances) that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> its thermal stability and, if applicable, its sensitivity to moisture.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/590">lengths of studies</a></span> chosen should be sufficient to cover <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, shipment, and subsequent use. the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover a minimum of 12 months™ duration on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three primary batches at the time of submission and should be continued for a period of time sufficient to cover the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. additional data accumulated during the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> period of the registration application should be submitted to the authorities if requested. data from the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition and, if 
appropriate, from the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition can be used to evaluate the effect of short term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (such as might occur during shipping).  long term, accelerated, and, where appropriate, intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for drug substances are detailed in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> below. the general case applies if the 
drug substance is not specifically covered by a subsequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span>.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions can be used if justified.  2.1.7.1. general case  study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at submission long term* 25°c ± 2°c/60% rh ± 5% rh 
or 
30°c ± 2°c/65% rh ± 5% rh 12 months intermediate** 30°c ± 2°c/65% rh ± 5% rh 6 months  accelerated 40°c ± 2°c/75% rh ± 5% rh 6 months  *it is up to the applicant to decide whether long term stability studies are performed at 25  2°c/60% rh  5% rh or 30°c  2°c/65% rh  5% rh.  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 4 **if 30°c  2°c/65% rh  5% rh is the long-term condition, there is no intermediate condition.  if long-term studies are conducted at 25°c ± 2°c/60% rh ± 5% rh and  ﬁsignificant changeﬂ occurs at any time during 6 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be conducted and evaluated against significant change criteria. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the 
intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should include all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, unless otherwise justified. the initial application should include a minimum of 6 months™ data from a 12-month 
study at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. ﬁsignificant changeﬂ for a drug substance is defined as failure to meet its specification. 2.1.7.2. drug substances intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a refrigerator study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at submission long term 5°c ± 3°c 12 months accelerated 25°c ± 2°c/60% rh ± 5% rh 6 months   data from refrigerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> according to the evaluation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, except where explicitly noted below. if significant change occurs between 3 and 6 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should be based on the real time data available at the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. if significant change occurs within the first 3 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a discussion should be provided to address the effect of short term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, e.g., during shipping or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>. this discussion can be supported, if appropriate, by further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch of the 
drug substance for a period shorter than 3 months but with more frequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> than usual. it is considered unnecessary to continue to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> a drug substance through 
6 months when a significant change has occurred within the first 3 months. 2.1.7.3. drug substances intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span> study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at submission long term - 20°c ± 5°c 12 months  for drug substances intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should be based on the real time data obtained at the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. in the 
absence of an accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for drug substances intended to be stored in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch at an elevated temperature (e.g., 5°c ± 3°c or 25°c ± 2°c) for an appropriate time period should be conducted to address the effect of short term excursions outside the proposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, e.g., during shipping or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>.  2.1.7.4. drug substances intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 5 drug substances intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c should be treated on a case-by-case basis. 2.1.8. stability commitment when available long term stability data on primary batches do not cover the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period granted at the time of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span>, a commitment should be made to continue the stability studies post <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> in order to firmly <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> 
period. where the submission includes long term stability data on three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches 
covering the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period, a post <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> commitment is considered unnecessary. otherwise, one of the following commitments should be made: 1. if the submission includes data from stability studies on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, a commitment should be made to continue these studies through the 
proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. 2. if the submission includes data from stability studies on fewer than three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, a commitment should be made to continue these studies 
through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period and to place additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, to a total of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three, on long term stability studies through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. 3. if the submission does not include stability data on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, a commitment should be made to place the first three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches on long 
term stability studies through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> used for long term studies for the stability commitment should 
be the same as that for the primary batches, unless otherwise scientifically justified. 2.1.9. evaluation the purpose of the stability study is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span>, based on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> a minimum of three 
batches of the drug substance and evaluating the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> (including, as appropriate, results of the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>), a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period applicable to all future batches of the drug substance manufactured 
under similar circumstances. the degree of variability of individual batches affects 
the confidence that a future <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch will remain within specification 
throughout the assigned re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. the data may show so little degradation and so little variability that it is apparent 
from looking at the data that the requested re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period will be granted. under these circumstances, it is normally unnecessary to go through the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis; providing a justification for the omission should be sufficient. an approach for analyzing the data on a quantitative attribute that is expected to 
change with time is to determine the time at which the 95% one-sided confidence limit for the mean curve intersects the acceptance criterion. if analysis shows that the 
batch-to-batch variability is small, it is advantageous to combine the data into one 
overall estimate. this can be done by first applying appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> (e.g., p values for level of significance of rejection of more than 0.25) to the slopes of the 
regression lines and zero time intercepts for the individual batches. if it is inappropriate to combine data from several batches, the overall re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should 
be based on the minimum time a batch can be expected to remain within acceptance criteria. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 6 the nature of any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will determine whether the data should be transformed for linear regression analysis. usually the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> can be represented by a linear, quadratic, or cubic function on an arithmetic or logarithmic 
scale. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> methods</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the goodness of fit of the data on 
all batches and combined batches (where appropriate) to the assumed degradation line or curve. limited extrapolation of the real time data from the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition 
beyond the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> range to extend the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period can be undertaken at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> 
time, if justified. this justification should be based on what is known about the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanism</a></span> of degradation, the results of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> under accelerated conditions, the goodness of fit of any <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1835">mathematical</a></span> model, batch size, existence of supporting stability data, etc. however, this extrapolation assumes that the same degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will continue to apply beyond the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> data. any evaluation should cover not only the assay, but also the levels of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and other appropriate attributes. 2.1.10. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> in accordance with relevant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> requirements. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should be based on the stability evaluation of the drug substance. where applicable, specific instructions should be provided, particularly for drug substances that cannot tolerate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezing</a></span>. terms such as ﬁambient conditionsﬂ or ﬁroom temperatureﬂ should be avoided.  a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should be derived from the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>, and a retest date should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5422">displayed</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> if appropriate. 2.2. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> 2.2.1. general the design of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies for the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be based on 
knowledge of the behavior and properties of the drug substance and from stability 
studies on the drug substance and on experience gained from clinical formulation studies. the likely changes on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> for the selection of attributes 
to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span>. 2.2.2. photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> one primary batch of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> if appropriate. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> conditions for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> are described in ich q1b. 2.2.3. selection of batches data from stability studies should be provided on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three primary batches of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  the primary batches should be of the same formulation and 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system as proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. the 
manufacturing process used for primary batches should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulate</a></span> that to be applied to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches and should provide <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> of the same quality and meeting the same specification as that intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. two of the three batches should be at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> pilot scale batches and the third one can be smaller, if justified. where 
possible, batches of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be manufactured by using different batches of the drug substance. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 7 stability studies should be performed on each individual strength and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> unless bracketing or matrixing is applied. other supporting data can be provided. 2.2.4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted on the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> (including, as appropriate, any secondary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>). any available studies carried out on the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> outside its immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> or in other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> materials can <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> a useful part of the stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> or can be considered as supporting <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>, respectively. 2.2.5. specification  specification, which is a list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, reference to analytical procedures, and proposed acceptance criteria, including the concept of different acceptance criteria for release and shelf life specifications, is addressed in ich q6a and q6b.  in addition, 
specification for degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> in a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is addressed in q3b. stability studies should include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of those attributes of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that are susceptible to change during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and are likely to influence quality, safety, and/or efficacy. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover, as appropriate, the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological attributes, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content (e.g., antioxidant, antimicrobial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span>), and functionality <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> (e.g., for a dose delivery system). analytical procedures should be fully validated and stability indicating. whether and 
to what extent replication should be performed will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the results of 
validation studies.  shelf life acceptance criteria should be derived from consideration of all available stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>. it may be appropriate to have justifiable differences between the shelf life and release acceptance criteria based on the stability evaluation and the 
changes <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>. any differences between the release and shelf life acceptance criteria for antimicrobial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content should be supported by a 
validated correlation of chemical content and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> effectiveness demonstrated 
during drug development on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in its final formulation (except for 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> concentration) intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>.  a single primary stability batch of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for antimicrobial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> effectiveness (in addition to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content) at the proposed shelf life for verification purposes, regardless of whether there is a difference between the release and shelf life 
acceptance criteria for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content. 2.2.6. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency for long term studies, frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be sufficient to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the stability profile of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> with a proposed shelf life of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 12 months, the frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should normally be every 3 months over the first year, every 6 months over the second year, and annually thereafter through the proposed shelf life. at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of three time points, including the initial and final time points (e.g., 0, 3, and 6 months), from a 6-month study is 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>. where an expectation (based on development experience) exists that results from accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> are likely to approach significant change criteria, 
increased <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted either by adding <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the final time point or by including a fourth time point in the study design. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 8 when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition is called for as a result of significant change at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of four time points, including the initial and final time points (e.g., 0, 6, 9, 12 months), from a 12-
month study is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>. reduced designs, i.e., matrixing or bracketing, where the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency is reduced or certain factor combinations are not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all, can be applied, if justified.  2.2.7. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions in general, a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be evaluated under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (with appropriate tolerances) that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> its thermal stability and, if applicable, its sensitivity to moisture or potential for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/590">lengths of studies</a></span> chosen should be sufficient to cover <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, shipment, and subsequent use.  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> after <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/148">constitution</a></span> or dilution, if applicable, should be conducted to provide <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> on the preparation, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, and in-use period of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/148">constituted</a></span> or diluted <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be performed on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/148">constituted</a></span> or diluted <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> through the proposed in-use period on primary batches as part of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies at initial and final time 
points and, if full shelf life long term data will not be available before submission, at 
12 months or the last time point for which data will be available.  in general, this 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> need not be repeated on commitment batches. the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover a minimum of 12 months™ duration on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three primary batches at the time of submission and should be continued for a period 
of time sufficient to cover the proposed shelf life. additional data accumulated during the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> period of the registration application should be submitted to the authorities if requested. data from the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition and, if appropriate, from the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition can be used to evaluate the effect of short term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (such as might occur during shipping).  long term, accelerated, and, where appropriate, intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are detailed in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> below.  the general case applies if the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is not specifically covered by a subsequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span>.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions can be used, if justified. 2.2.7.1. general case study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at 
submission long term* 25°c ± 2°c/60% rh ± 5% rh
or 
30°c ± 2°c/65% rh ± 5% rh 12 months intermediate** 30°c ± 2°c/65% rh ± 5% rh 6 months  accelerated 40°c ± 2°c/75% rh ± 5% rh 6 months  *it is up to the applicant to decide whether long term stability studies are performed at 25  2°c/60% rh  5% rh or 30°c  2°c/65% rh  5% rh.  **if 30°c  2°c/65% rh  5% rh is the long-term condition, there is no intermediate condition. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 9  if long-term studies are conducted at 25°c ± 2°c/60% rh ± 5% rh and  ﬁsignificant changeﬂ occurs at any time during 6 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be conducted and evaluated against significant change criteria. the initial application should include a minimum of 6 months™ data from a 12-month study at the 
intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. in general, ﬁsignificant changeﬂ for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is defined as: 1. a 5% change in assay from its initial value; or failure to meet the acceptance criteria for potency when using <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1304">immunological</a></span> procedures;  2. any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>™s exceeding its acceptance criterion;  3. failure to meet the acceptance criteria for appearance, physical attributes, and functionality <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> (e.g., color, phase separation, resuspendibility, caking, 
hardness, dose delivery per actuation); however, some changes in physical attributes (e.g., softening of suppositories, melting of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>) may be expected under accelerated conditions;  and, as appropriate for the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>: 4. failure to meet the acceptance criterion for ph; or 5. failure to meet the acceptance criteria for dissolution for 12 dosage units. 2.2.7.2. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> sensitivity to moisture or potential for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> is not a concern for drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> that provide a permanent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4819">barrier</a></span> to passage of moisture or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>. thus, stability studies for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> stored in impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> can be conducted under any controlled or ambient humidity condition.  2.2.7.3. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> aqueous-based <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> should be evaluated for potential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> in addition to physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological stability. this evaluation can be carried out under conditions of low relative humidity, as discussed below. ultimately, it should be demonstrated that aqueous-based drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> stored in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> can withstand low 
relative humidity environments.  other comparable approaches can be developed and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> for non-aqueous, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>-based <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>.  study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at 
submission long term*  25°c ± 2°c/40% rh ± 5% rh or 
30°c ± 2°c/35% rh ± 5% rh 12 months intermediate** 30°c ± 2°c/65% rh ± 5% rh 6 months stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 10 accelerated  40°c ± 2°c/not more than (nmt) 25% rh 6 months  *it is up to the applicant to decide whether long term stability studies are performed at 25  2°c/40% rh  5% rh or 30°c  2°c/35% rh  5% rh.  **if 30°c  2°c/35% rh  5% rh is the long-term condition, there is no intermediate condition.  for long-term studies conducted at 25°c ± 2°c/40% rh ± 5% rh, additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be performed as described under the general case to evaluate the temperature effect at 30°c if  significant change other than <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> occurs during the 6 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. a significant change in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> alone at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition does not necessitate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. however, data should be provided to demonstrate that the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> will not have significant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> throughout the proposed shelf life if stored at 25°c and the reference relative humidity of 40% rh. a 5% <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> from its initial value is considered a significant change for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> after an equivalent of 3 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at 40°c/nmt 25% rh.  however, for small <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> (1 ml or less) or unit-dose <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> of 5% or more after an equivalent of 3 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at 
40°c/nmt 25% rh may be appropriate, if justified. an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> approach to studying at the reference relative humidity as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> in the table above (for either long term or accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>) is performing the stability studies under higher relative humidity and deriving the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> at the reference relative humidity through calculation. this can be achieved by experimentally determining the permeation coefficient for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system or, as shown in the example below, using the calculated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rates between the two humidity conditions at the same temperature. the permeation coefficient for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system can be experimentally determined by using the worst case scenario (e.g., the most diluted of a series of concentrations) for the proposed drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  example of an approach for determining <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>: for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in a given <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size, and fill, an appropriate approach for deriving the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate at the reference relative humidity is to multiply the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate measured at an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> relative humidity at the same temperature by a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span> shown in the table below. a linear <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate at the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> relative humidity over the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> period should be demonstrated.  for example, at a given temperature, e.g., 40°c, the calculated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at nmt 25% rh is the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate measured at 75% rh multiplied by 3.0, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponding</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> relative humidity reference relative humidity <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rates at a given temperature  60% rh 25% rh 1.9  60% rh 40% rh 1.5 stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 11 65% rh 35% rh 1.9 75% rh 25% rh 3.0  valid <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratios</a></span> at relative humidity conditions other than those shown in the table above can also be used.   2.2.7.4. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a refrigerator study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at submission long term 5°c ± 3°c  12 months accelerated 25°c ± 2°c/60% rh ± 5% rh 6 months   if the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>, appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> should be provided to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assess</a></span> the extent of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>. data from refrigerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> according to the evaluation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, except where explicitly noted below. if significant change occurs between 3 and 6 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, the proposed shelf life should be based on the real time data available from the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. if significant change occurs within the first 3 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a discussion should be provided to address the effect of short term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, e.g., during shipment and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>. this discussion can be supported, if appropriate, by further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> for a period shorter than 3 months but with more frequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> 
than usual. it is considered unnecessary to continue to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> through 6 months when a significant change has occurred within the first 3 months. 2.2.7.5. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span> study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition minimum time period covered by data at submission long term - 20°c ± 5°c 12 months  for drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, the shelf life should be based on the real time data obtained at the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. in the absence of an 
accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended to be stored in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch at an elevated temperature (e.g., 5°c ± 3°c or 25°c ± 2°c) for an appropriate time period should be conducted to address the effect of short term excursions outside the proposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. 2.2.7.6. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c  drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c should be treated on a case-by-case basis. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 12 2.2.8. stability commitment when available long term stability data on primary batches do not cover the proposed shelf life granted at the time of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span>, a commitment should be made to continue the stability studies post <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> in order to firmly <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the shelf life. where the submission includes long term stability data from three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches 
covering the proposed shelf life, a post <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> commitment is considered 
unnecessary. otherwise, one of the following commitments should be made: 1. if the submission includes data from stability studies on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, a commitment should be made to continue the long term studies through the proposed shelf life and the accelerated studies for 6 months. 2. if the submission includes data from stability studies on fewer than three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, a commitment should be made to continue the long term studies through the proposed shelf life and the accelerated studies for 6 months, 
and to place additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, to a total of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three, on long term stability studies through the proposed shelf life and on accelerated studies for 6 months. 3. if the submission does not include stability data on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, a commitment should be made to place the first three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches on long 
term stability studies through the proposed shelf life and on accelerated studies for 6 months. the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> used for studies on commitment batches should be the same as that for the primary batches, unless otherwise scientifically justified. where intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is called for by a significant change at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for the primary batches, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on the commitment batches can be conducted at either the intermediate or the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. however, if significant change occurs at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition on the commitment batches, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should also be conducted. 2.2.9. evaluation a systematic approach should be adopted in the presentation and evaluation of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>, which should include, as appropriate, results from the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, including particular attributes of the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> (for example, dissolution rate for solid oral dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>).  the purpose of the stability study is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span>, based on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> a minimum of three 
batches of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, a shelf life and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> instructions applicable to all future batches of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufactured and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> under similar 
circumstances. the degree of variability of individual batches affects the confidence that a future <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch will remain within specification throughout its shelf life. where the data show so little degradation and so little variability that it is apparent from looking at the data that the requested shelf life will be granted, it is normally unnecessary to go through the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis; providing a justification for the omission should be sufficient. an approach for analyzing data of a quantitative attribute that is expected to change with time is to determine the time at which the 95 one-sided confidence limit for the mean curve intersects the acceptance criterion. if analysis shows that the batch-to-
batch variability is small, it is advantageous to combine the data into one overall stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 13 estimate. this can be done by first applying appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> (e.g., p values for level of significance of rejection of more than 0.25) to the slopes of the regression 
lines and zero time intercepts for the individual batches. if it is inappropriate to combine data from several batches, the overall shelf life should be based on the 
minimum time a batch can be expected to remain within acceptance criteria. the nature of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will determine whether the data should be 
transformed for linear regression analysis. usually the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> can be 
represented by a linear, quadratic, or cubic function on an arithmetic or logarithmic 
scale. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> methods</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the goodness of fit on all batches 
and combined batches (where appropriate) to the assumed degradation line or curve. limited extrapolation of the real time data from the long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition 
beyond the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> range to extend the shelf life can be undertaken at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> time, if justified. this justification should be based on what is known about the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanisms</a></span> of degradation, the results of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> under accelerated conditions, the goodness of fit of any <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1835">mathematical</a></span> model, batch size, existence of supporting stability data, etc. however, this extrapolation assumes that the same degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will continue to apply beyond the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> data. any evaluation should consider not only the assay but also the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and other appropriate attributes. where appropriate, attention should be paid to reviewing the adequacy of the mass balance and different stability and degradation performance. 2.2.10. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> in accordance with relevant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> requirements. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should be based on the stability evaluation of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. where applicable, specific instruction should be provided, particularly for drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> that cannot tolerate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezing</a></span>. terms such as ﬁambient conditionsﬂ or ﬁroom temperatureﬂ should be avoided. there should be a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> link between the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> and the 
demonstrated stability of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  an expiration date should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5422">displayed</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>. 3. glossary  the following definitions are provided to facilitate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1482">interpretation</a></span> of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.  accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> studies designed to increase the rate of chemical degradation or physical change of a 
drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> by using exaggerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions as part of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies. data from these studies, in addition to long term stability studies, can be used to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assess</a></span> longer term chemical effects at non-accelerated conditions and to evaluate the effect of short term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions such as might occur during shipping. results from accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> studies are not always predictive of physical changes. bracketing the design of a stability schedule such that only <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> of certain 
design factors, e.g., strength, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> size, are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all time points as in a full design. the design assumes that the stability of any intermediate levels is 
represented by the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>. where a range of strengths is to stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 14 be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>, bracketing is applicable if the strengths are identical or very closely related in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> (e.g., for a tablet range made with different compression weights of a similar basic granulation, or a capsule range made by filling different plug fill weights of the same basic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> into different size capsule shells). bracketing can be applied to different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes or different fills in the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span> the four zones in the world that are distinguished by their characteristic prevalent annual <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> conditions. this is based on the concept described by w. grimm (drugs made in germany, 28:196-202, 1985 and 29:39-47, 1986).  commitment batches <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches of a drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> for which the stability studies are initiated or completed post <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> through a commitment made in the registration application. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system the sum of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> components that together <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contain</a></span> and protect the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>. this includes primary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> components and secondary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> components, if the latter are intended to provide additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span> to the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> system is equivalent to a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system. dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> a pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> type (e.g., tablet, capsule, solution, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">cream</a></span>) that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> a drug substance generally, but not necessarily, in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">association</a></span> with excipients. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> in the final immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. drug substance the unformulated drug substance that may subsequently be formulated with excipients to produce the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>. excipient anything other than the drug substance in the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>. expiration date the date placed on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> of a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/71"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5573">product</a></span></a></span> designating</a></span></a></span> the time prior to which a batch of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is expected to remain within the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> shelf life 
specification if stored under defined conditions, and after which it must not be used. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 15 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies long term and accelerated (and intermediate) studies undertaken on primary and/or commitment batches according to a prescribed stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> or confirm the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period of a drug substance or the shelf life of a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> that provide a permanent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4819">barrier</a></span> to the passage of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1139">gases</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>, e.g., <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> aluminum <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4575">tubes</a></span> for semi-solids, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4676">glass</a></span> ampoules for solutions.  intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> studies conducted at 30°c/65% rh and designed to moderately increase the rate of chemical degradation or physical changes for a drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> intended to be stored long term at 25°c. long term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> stability studies under the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf life proposed (or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span>) for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span>. mass balance the process of adding together the assay value and levels of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> to see how closely these add up to 100% of the initial value, with due consideration of the margin of analytical error. matrixing the design of a stability schedule such that a selected subset of the total number of 
possible <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for all factor combinations is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at a specified time point. at a 
subsequent time point, another subset of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for all factor combinations is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>. the design assumes that the stability of each subset of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> represents the 
stability of all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at a given time point. the differences in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for the 
same drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be identified as, for example, covering different batches, different strengths, different sizes of the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system, and, possibly in some cases, different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems. mean kinetic temperature a single derived temperature that, if maintained over a defined period of time, affords the same thermal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8458">challenge</a></span> to a drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> as would be experienced over a range of both higher and lower temperatures for an equivalent 
defined period. the mean kinetic temperature is higher than the arithmetic mean temperature and takes into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> the arrhenius equation.  when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> the mean kinetic temperature for a defined period, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formula</a></span> of j. d. haynes (j. pharm. sci., 60:927-929, 1971) can be used. new molecular entity an active pharmaceutical substance not previously <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contained</a></span> in any drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> registered with the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5502">regional</a></span></a></span> authority</a></span> concerned.  a new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3758">salt</a></span>, ester, or non-covalent-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2098">bond</a></span> derivative of an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> drug substance is considered a new molecular entity for the purpose of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> under this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span>. stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 16 pilot scale batch a batch of a drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufactured by a procedure fully representative of and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulating</a></span> that to be applied to a full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> scale batch. for solid oral dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>, a pilot scale is generally, at a minimum, one-tenth that of a full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> scale or 100,000 tablets or capsules, whichever is the larger. primary batch a batch of a drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> used in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability study, from which stability data are submitted in a registration application for the purpose of 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf life, respectively.  a primary batch of a drug substance should be at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> a pilot scale batch.  for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, two of the three 
batches should be at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> pilot scale batch, and the third batch can be smaller if it is 
representative with regard to the critical manufacturing steps.  however, a primary 
batch may be a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch a batch of a drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufactured at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> scale by 
using <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> equipment in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> facility as specified in the application. re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> date the date after which <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> of the drug substance should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span> to ensure 
that the material is still in compliance with the specification and thus suitable for use in the manufacture of a given drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period the period of time during which the drug substance is expected to remain within its specification and, therefore, can be used in the manufacture of a given drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, provided that the drug substance has been stored under the defined conditions. after this period, a batch of drug substance destined for use in the manufacture of a drug 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for compliance with the specification and then used 
immediately. a batch of drug substance can be re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> multiple times and a 
different portion of the batch used after each re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>, as long as it continues to comply with the specification.  for most <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> substances known to be labile, it is more appropriate to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> a shelf life than a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. the same 
may be true for certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1997">antibiotics</a></span>. semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> that allow the passage of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>, usually <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span>, while preventing solute <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanism</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> transport occurs by absorption into one <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> surface, diffusion through the bulk of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> material, and desorption from the other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4510">surface.  transport</a></span> is driven by a partial-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2599">pressure</a></span> gradient.  examples of semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> bags and semi-rigid, low-density polyethylene (ldpe) pouches for large volume parenterals (lvps), and ldpe ampoules, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/722">bottles</a></span>, 
and vials. shelf life (also referred to as expiration dating period) the time period during which a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is expected to remain within the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> shelf life specification, provided that it is stored under the conditions defined on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>. specification stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 17 see q6a and q6b. specification œ release the combination of physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> and acceptance criteria that determine the suitability of a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> at the time of its release. specification - shelf life the combination of physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> and acceptance criteria that determine the suitability of a drug substance throughout its re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period, or that a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should meet throughout its shelf life. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition tolerances the acceptable variations in temperature and relative humidity of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> facilities for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies. the equipment should be capable of controlling the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition within the ranges defined in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. the actual temperature and humidity (when controlled) should be monitored during stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>. short term spikes due to opening of doors of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> facility are accepted as unavoidable. the effect of excursions due to equipment failure should be addressed, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> if 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judged</a></span> to affect stability results. excursions that exceed the defined tolerances for more than 24 hours should be described in the study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> and their effect <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>. stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (drug substance) studies undertaken to elucidate the intrinsic stability of the drug substance. such <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is part of the development strategy and is normally carried out under more severe conditions than those used for accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>. stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>) studies undertaken to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assess</a></span> the effect of severe conditions on the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  such studies include photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (see ich q1b) and specific <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, (e.g., metered dose inhalers, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, emulsions, refrigerated aqueous <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquid</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>). supporting data data, other than those from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies, that support the analytical procedures, the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf life, and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span>.  such data include (1) stability data on early synthetic route batches of drug 
substance, small scale batches of materials, investigational formulations not proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>, related formulations, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> presented in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> and closures other than those proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>; (2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> regarding <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> results on 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>; and (3) other scientific <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationales</a></span>.  4. references  ich q1b: ﬁphotostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span> ich q1c:  ﬁstability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formsﬂ</a></span> ich q3a:  ﬁimpurities in new drug substancesﬂ stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 18 ich q3b:  ﬁimpurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span> ich q5c:  ﬁstability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span> ich q6a: ﬁspecifications: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> procedures and acceptance criteria for new drug substances and new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>: chemical substancesﬂ ich q6b: ﬁspecifications: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> procedures and acceptance criteria for new drug substances and new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span> </body><html>